SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Aardvark Therapeutics, Inc. Common Stock (AARD) has a negative trailing P/E of -1.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 7.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -68.55%, forward earnings yield 13.14%.
Criteria proven by this page:
- VALUE (100/100, Pass) — analyst target implies upside (+477.4%).
- Forward P/E 7.6 — analysts expect a return to profitability with estimated EPS of $0.67 for FY2030.
- Trailing Earnings Yield -68.55% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 13.14% as earnings recover.
- Analyst consensus target $29.33 (+477.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 50/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AARD
Valuation Multiples
P/E (TTM)-1.5
Forward P/E7.6
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.79
P/S Ratio0.00
EV/EBITDA-0.6
Per Share Data
EPS (TTM)$-2.64
Forward EPS (Est.)$0.67
Book Value / Share$4.89
Revenue / Share$0.00
FCF / Share$-2.49
Yields & Fair Value
Earnings Yield-68.55%
Forward Earnings Yield13.14%
Dividend Yield0.00%
Analyst Target$29.33 (+477.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2022 |
-10.3 |
0.00 |
-4.99 |
0.00 |
- |
| 2023 |
-25.6 |
0.43 |
-5.31 |
0.00 |
- |
| 2024 |
-9.0 |
-0.05 |
-3.38 |
0.00 |
- |
| 2025 |
-4.5 |
-0.05 |
2.42 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$-1.39 |
$0.00 |
$-13.56M |
- |
| 2023 |
$-0.56 |
$0.00 |
$-7.21M |
- |
| 2024 |
$-1.59 |
$0.00 |
$-20.59M |
- |
| 2025 |
$-2.93 |
$0.00 |
$-57.59M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-3.45 |
$-3.96 – $-2.60 |
$300K |
$300K – $300K |
9 |
| 2027 |
$-3.56 |
$-6.14 – $-2.24 |
$1.14M |
$1.14M – $1.14M |
8 |
| 2028 |
$-3.22 |
$-6.85 – $-1.56 |
$22.75M |
$21.9M – $23.6M |
7 |
| 2029 |
$-1.58 |
$-1.58 – $-1.58 |
$88.97M |
$88.97M – $88.97M |
2 |
| 2030 |
$0.67 |
$0.67 – $0.67 |
$277.72M |
$277.72M – $277.72M |
5 |
